BioMarin Pharmaceutical Inc.

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

17 Oct 2018 10:48:59 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

07 Aug 2018 10:28:48 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

17 Jul 2018 12:44:02 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

16 Jul 2018 09:47:26 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

13 Jul 2018 10:07:30 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

12 Jul 2018 09:45:00 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

11 Jul 2018 12:49:18 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

10 Jul 2018 09:44:47 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

22 Jun 2018 09:44:53 By NetDania Notify

BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia

12 Dec 2016 08:29:22 By Nasdaq GlobeNewswire

BioMarin to Attend Three Upcoming Investor Conferences

03 Nov 2016 08:30:46 By Nasdaq GlobeNewswire

BioMarin Announces Third Quarter 2016 Financial Results

27 Oct 2016 16:03:46 By Nasdaq GlobeNewswire

BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting

19 Oct 2016 17:01:21 By Nasdaq GlobeNewswire

UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A

13 Oct 2016 16:01:29 By Nasdaq GlobeNewswire

BioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET

11 Oct 2016 08:31:09 By Nasdaq GlobeNewswire

BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics

21 Sep 2016 08:54:15 By Nasdaq GlobeNewswire

BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease

15 Sep 2016 08:38:09 By Nasdaq GlobeNewswire

BioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual Meeting

08 Sep 2016 04:30:29 By Nasdaq GlobeNewswire

BioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease

06 Sep 2016 16:06:27 By Nasdaq GlobeNewswire

BioMarin to Attend Upcoming Investor Conferences

31 Aug 2016 08:30:53 By Nasdaq GlobeNewswire